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Abstract
Background: Automated screening of Papanicolaou tests (Pap tests) improves the productivity of
cytopathology laboratories. The ThinPrep® Imaging System (TIS) has been widely adopted primarily
for this reason for use on ThinPrep® Pap tests (TPPT). However, TIS may also influence the
interpretation of Pap tests, leading to changes in the frequency of various interpretive categories.
The effect of the TIS on rates of TPPT interpretation as atypical squamous cells of undetermined
significance (ASC-US) is of concern because any shift in the frequency of ASC-US will alter the
sensitivity and specificity of the Pap test. We have sought to determine whether automated
screening of TPPT has altered ASC-US rates in our institution when compared with manual
screening (MS) of TPPT.
Methods: A computerized search for all ASC-US with reflex Human Papillomavirus (HPV) testing
over a one-year-period (7/1/06 to 6/30/07) was conducted. Cases included both TPPT screened
utilizing TIS and screened manually. HPV test results for both groups were recorded. Pertinent
follow-up cervical cytology and histology results were retrieved for the period extending to 11/30/
07. Automated screening was in clinical use for 10 months prior to the start of the study.
Results: Automated screening was performed on 23,103 TPPT, of which 977 (4.23%) were
interpreted as ASC-US. Over the same period, MS was performed on 45,789 TPPT, of which 1924
(4.20%) were interpreted as ASC-US. Reflex HPV testing was positive for high risk (HR) types in
47.4% of the TIS cases and 50.2% of MS cases. Follow-up cervical dysplasia found by colposcopy
was also distributed proportionally between the two groups. Cervical intraepithelial neoplasia
(CIN) was found on follow-up biopsy of 20.1% of the TIS cases (5.2% CIN 2/3) and 21.2% of MS
cases (5.1% CIN 2/3). None of these differences were statistically significant.
Conclusion: Use of the ThinPrep® Imaging System did not appreciably change ASC-US rates or
follow-up reflex HPV test results in our laboratory. This demonstrates that the benefits of
automated screening may be obtained without increasing the rate of referral to colposcopy for
ASC-US follow-up.
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Introduction
Automated screening of ThinPrep®  Papanicolaou Tests
(TPPT) has become increasingly common in clinical prac-
tice. The ThinPrep® Imaging System (TIS) (Hologic Corp.
[previously Cytyc Corp.], Marlborough, MA) is the most
widely used and studied automated system currently
available. The operational details of the TIS have previ-
ously been published [1]. Briefly, the TIS is an automated
imaging and review system indicated for primary screen-
ing of TPPT. The System consists of three components: an
image processor, a PC-based computer that runs on Win-
dows NT (Microsoft Corp., Redmond, WA), and a review
microscope with a mechanical stage and electronic dot-
ting capability. The TIS uses algorithms to select 22 fields
of view (FOV) which include the cells most likely to be
dysplastic according to computer imaging characteristics.
These fields are then reviewed by a cytotechnologist (CT).
If all cells seen in the 22 FOV are considered normal the
case is signed out as negative by the CT. Since most slides
fall into this category, thereby reducing the amount of
time spent on screening, the TIS greatly reduces workload
and improves laboratory productivity. If any cells within
the 22 FOV are considered abnormal the entire slide is
manually re-screened utilizing the automated micro-
scope. The TIS has an additional benefit: increased sensi-
tivity. Published studies have consistently shown that this
system leads to the discovery of a higher proportion of
slides with dysplastic cells leading to an interpretation of
either low-grade or high-grade squamous intraepithelial
lesion (LSIL or HSIL) [2-8]. This increase in sensitivity
does not appear to come at the expense of specificity, as
follow-up biopsies show a corresponding increase in the
frequency of discovery of dysplastic lesions [3].
The effect of the TIS on rates of atypical squamous cells of
undetermined significance (ASC-US), however, is less
clear. Two studies reported an increase in the ASC-US rate
[7,8], while two others reported a decrease [5,6] attributa-
ble to the TIS. These contrasting results occurred despite
use of a similar study design that compared the ASC-US
rate during the one-year periods before and after the intro-
duction of the TIS into their respective laboratories [5-8].
ASC-US is the most common abnormal interpretation of
Pap tests. Consequently, this category accounts for the
highest proportion of the cervical intraepithelial neopla-
sia (CIN) 2 and 3 detected by screening (38.8% of cases in
the study by Kinney and coworkers [9]). ASC-US rates also
heavily influence the cost of cervical cancer screening pro-
grams. Current recommendations advise reflex HPV test-
ing for ASC-US found in women over age 20 years, with
subsequent colposcopic examination in women positive
for high-risk (HR) types [10]. Given these facts, any effect
of the TIS on the frequency of ASC-US interpretations
could have significant clinical and public health implica-
tions.
If the ASC-US rate were to increase as a result of TIS use,
the sensitivity of the Pap tests would almost certainly rise.
However, the cost of cervical cancer screening programs
would also rise. At the very least, the number of reflex HPV
tests would increase. Referrals to colposcopy could also
increase if the number of reflex HPV tests positive for HR-
types went up as a result of more frequent testing.
Depending on the size of these increases, the rise in costs
could become substantial.
A decrease in the ASC-US rate as a result of using the TIS
would lead to a regrettable loss of Pap test sensitivity. If
the frequency of LSIL and HSIL interpretations increased
simultaneously, however, this could at least partially off-
set the sensitivity losses. The costs of Pap test screening
programs would reflect the overall sensitivity of the test,
with declining ASC-US rates probably resulting in a less
costly system.
The introduction of reflex HPV testing for ASC-US into
clinical practice has created a new metric for the evalua-
tion of ASC-US rates: the frequency of results positive for
high-risk viral types. The ALTS trial, which established the
efficacy of HPV triage, also set a benchmark for HR-HPV
positive rates in ASC-US of 50% [11]. At present there is
considerable variation in HR-HPV rates between laborato-
ries [12] and between individual cytologists [13,14].
However, some academic laboratories have already estab-
lished an average HR-HPV positive rate similar to that of
the ALTS trial [13,14]. Many cytologists are interested in
using this metric to try to achieve more standardization of
the ASC-US category. Ultimately, it is hoped, this may
enable the cytology community to create reproducible
sensitivity and specificity characteristics for the Pap test.
This study evaluates the effect of the TIS on ASC-US rates
on TPPT and subsequent follow-up in a screening popula-
tion arbitrarily divided between manual and TIS-assisted
screening, over a single time period, with reflex HPV test
result feedback.
Methods
Our laboratory processes approximately 70,000 Pap tests
per year, of which more than 95% are TPPT with the
remainder consisting of conventional smears and Sure-
Path®  liquid-based preparations (BD, Franklin Lakes,
MD). This study focuses on TPPT. We receive specimens
from a mix of clinical settings which include both low-risk
populations (privately insured women) and high-risk
populations (prisoners and recipients of subsidized
women's health services). Specimens were examined by a
team of 12 CTs and 4 cytopathologists during the studyCytoJournal 2008, 5:10 http://www.cytojournal.com/content/5/1/10
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period. The ASC:SIL ratio for the laboratory was 1.3 in
2006 and 2007.
The TIS has been in clinical use in our laboratory since
September of 2005. Although all TPPT were processed
through the imager during the study period, many were
manually screened because of an insufficient number of
special automated microscopes. Selection for MS was
made essentially randomly by the CT with no systematic
bias we are aware of. Cases screened with the assistance of
the TIS are identified by a standardized comment
included in the reports of all such cases.
Reflex HPV testing is performed by the Hybrid Capture 2
method (Digene, Gaithersburg, MD) using a mixed probe
targeting 13 cancer-associated HR-HPV types. The test is
performed by the microbiology section of our department
based on the manufacturer's protocol. Specimens without
sufficient material remaining in the vial, approximately 4
mL, were excluded from this study.
The cytopathologists in our laboratory were aware of the
results of reflex HPV testing for their ASC-US cases. The
goal of the laboratory was to maintain a HR-HPV positiv-
ity rate of close to 50% during this period.
Cervical biopsy specimens are reviewed by the surgical
pathology department which includes 19 pathologists.
The computerized laboratory records for our institution
were reviewed for the one-year period from July 1, 2006
to June 30, 2007 to find all TPPT interpreted as ASC-US.
Follow-up reflex HPV test and biopsy results, as well as
additional Pap test results for the time period extending
from July 1, 2006 to November 30, 2007, were also
reviewed. The institutional review board authorized this
study.
The statistical calculations employed the Yates correction
of the chi-square test using an online resource [15]. We
considered findings to be statistically significant at p-val-
ues < 0.05.
Results
During the study period, 68,898 Pap tests were performed
in our laboratory. Of these, 2,901 tests from 2,716 women
(age range: 15–85 years; mean age: 34 years; median age:
30 years), were interpreted as ASC-US and had a reflex
HPV test.
One third (33.5%) of the cases were screened with the
assistance of the TIS. The comparative rates of ASC-US
interpretations for the two groups as well as the reflex HPV
test results are displayed in Table 1. The difference in the
ASC-US rates is miniscule (4.23% for TIS cases versus
4.20% for MS) and not statistically significant (p = 0.888).
HR-HPV positive rates in ASC-US are also very similar in
the two groups (47.4% for the TIS versus 50.2% for MS),
again without statistical significance (p = 0.383).
Among HR-HPV positive cases, follow-up biopsy results
were available for almost half of the women as shown in
Table 2. Just over 5% of the HR-HPV positive women in
both groups (5.18% for the TIS and 5.07% for MS; p =
0.920) had CIN 2 or 3 found by histological sampling
during this short follow-up period. In addition, three
cases of adenocarcinoma in-situ were found in follow-up
of these women, two in the TIS group (including one in an
adolescent) and one in the MS group.
Among women negative for HR-HPV, 80 had histological
follow-up, including 25 women screened by the TIS and
55 by MS. Among these there were 10 cases of dysplasia
(CIN 1, 8; CIN 2, 2) in the TIS group and 11 cases (CIN 1,
10 and CIN 3, 1) in the MS group.
In the subset of HR-HPV positive women who did not
have histological sampling, 387 had follow-up Pap tests
available, including 132 women screened by the TIS and
255 by MS. Of these a few had an interpretation of dyspla-
sia in both the TIS group (LSIL, 23; HSIL, 1) and the MS
group (LSIL, 55; HSIL, 1).
Since reflex HPV testing in adolescent women is now
deemed "unacceptable" according to the recently revised
ASCCP guidelines [10] we have re-analyzed our data to
gauge the effect of removing them from the reflex-tested
population. The data for only those women aged more
than 20 years is presented in Table 3. Eliminating reflex
HPV tests for adolescents would have reduced our HPV
test rate by 11.7% in the TIS group and 14.4% in the MS
group (p = 0.042). HR-HPV positive result rates would
Table 1: Comparison of the automated and manual screening methods
Method Total Tests ASC-US HR-HPV Positive
Number % of Total Number % of ASC-US % of Total
TIS 23103 977 4.23% 463 47.4% 2.00%
MS 45789 1924 4.20% 965 50.2% 2.11%
The distribution of ASC-US cases screened by the ThinPrep® Imaging System (TIS) and by manual screening (MS) alone with the follow-up reflex 
HPV results.CytoJournal 2008, 5:10 http://www.cytojournal.com/content/5/1/10
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have remained comparable for both groups (44.8% for
the TIS versus 46.0% for MS; p = 0.572).
Discussion
Previous studies of the clinical performance of the TIS
have yielded conflicting results about the effect on the
ASC-US rate. Most studies have used a non-synchronous
design, with the Pap test interpretations from the year
before the introduction of the TIS compared with the
interpretations from the first year of TIS use. Using this
method, Lozano found an increase in the ASC-US rate
from 4.09% to 6.52% (p < 0.001) [7] and Dziura and
coworkers found an increase from 3.1% to 4.0% (p-value
not given) [6] after the introduction of the TIS to their lab-
oratories. Both demonstrated a corresponding decrease in
the frequency of detection of HR-HPV on reflex testing.
Conversely, Miller and coworkers found a decrease in the
ASC-US rate from 5.59% to 4.72% (p < 0.0001) associ-
ated with an increase in the HR-HPV positive rate [8]. Chi-
vukula and coworkers also found a decrease in the ASC-
US rate, from 8.79% to 8.70% (p-value not given), though
they did not report the follow-up HPV test results [5].
These studies, in contrast to ours, have the strength of
allowing for and measuring changes in clinical practice
following the introduction of the TIS. If the TIS somehow
revolutionized the interpretation of Pap tests, these stud-
ies would be more likely to detect the difference. How-
ever, this design of comparing consecutive years also has
serious problems. Any change in clinical practice from
year to year will affect the results, confounding the analy-
sis of the influence of the TIS alone.
Lozano demonstrated an impressive "learning curve"
effect in the early months of TIS use which corresponded
to a sizeable, sudden change in both the ASC-US rate and
the follow-up HPV results [7]. This "learning curve" could
potentially have influenced the outcomes of all four stud-
ies. Significantly, the ASC-US rate remained higher and
the reflex HR-HPV rate lower in the final month of the
study than in the previous year. This would indicate that
the "learning curve" alone was not responsible for the
entirety of the observed changes in the ASC-US rate in the
Lozano study and, therefore, probably does not account
for all of the effects on ASC-US rates reported in the other
year-to-year comparison studies.
Another factor to consider is the influence of changing
interpretive thresholds. Although it is not feasible to spec-
ulate on the cause of such changes, the consistent obser-
vation that the HR-HPV positivity rate changed in accord
with the ASC-US rate in all three studies makes this mech-
anism a likely explanation for the findings. Lowered
thresholds for ASC-US will increase the ASC-US rate and
decrease the HR-HPV frequency in reflex testing, with
raised ASC-US thresholds having the opposite effect.
These scenarios correspond to the findings of the three
studies that reported follow-up HPV results [6-8]. Of
course, thresholds for LSIL also influence the HPV follow-
up of ASC-US, but these three studies reported similar 37–
46% increases in the LSIL rates from one year to another
[6-8]. Therefore changes in LSIL thresholds are unlikely to
account for their very different HPV testing results.
Our study, in comparison with these, has the merit of syn-
chronous analysis of the TIS and MS groups. This should
minimize interpretive threshold differences and other
potentially confounding factors such as changes in cytol-
ogy staffing or differing specimen sources over time. We
also designed our study to begin well after the introduc-
tion of the TIS to our laboratory (10 months) to eliminate
any potential "learning curve" effect.
Only a few studies have analyzed the effects of the TIS on
ASC-US rates using single-patient comparisons [3,4].
Unfortunately, these shed little light on the question at
hand. Biscotti and coworkers screened the same slides
manually and with the assistance of the TIS [3]. They
found an increase in the ASC-US rate in the TIS subset
upon initial review, but a decrease in the same subset fol-
lowing adjudication by multiple pathologists. Davey and
Table 2: Biopsy results for the high-risk HPV positive subset
Method Total ASC-US Biopsies % Biopsied CIN 1 CIN 2/3
Number % of Total Number % of Total
TIS 463 209 45.1% 69 14.9% 24 5.18%
MS 965 435 45.1% 156 16.2% 49 5.07%
Follow-up biopsy results for the ASC-US cases screened by the TIS and by MS alone among women positive for HR-HPV.
Table 3: Comparison of the automated and manual screening 
methods in women over age 20
Method ASC-US HR-HPV Positive
Total + Biopsy CIN 1 CIN 2/3
TIS 863 387 180 60 22
MS 1647 758 366 129 42
The distribution of ASC-US cases with follow-up HPV testing and 
biopsy results for women aged more than 20 years and screened by 
the TIS or by MS alone.CytoJournal 2008, 5:10 http://www.cytojournal.com/content/5/1/10
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coworkers compared concurrent TPPT slides run through
the TIS with conventional smears taken simultaneously
from the same women [4]. They found a higher ASC-US
rate in the slides screened with TIS assistance but the dif-
ferences between TPPT and conventional cytology con-
found the results because liquid-based testing itself may
have influenced the ASC-US rate relative to smeared slides
independent of the effect of the TIS.
Another significant difference between our study and
those performed previously was our use of reflex HPV test
results as a quality metric in our laboratory. We were con-
sciously trying to remain near the benchmark of 50% HR-
HPV positive ASC-US interpretations established by the
ALTS trial [11]. This probably contributed to our result of
essentially equivalent ASC-US rates in the TIS and MS
cases. Our data support the conclusion that by applying
this metric the ASC-US rate can be maintained at a stable
level regardless of screening method.
Some criticisms of the ALTS trial have been put forward.
The patients used in the trial were younger and at higher
risk for HPV exposure than the population at large [16],
raising the possibility that the results may not be univer-
sally applicable. Furthermore, unlike some trials [17,18],
not all enrolled women underwent standardized colpos-
copy and biopsy, leading to verification bias. While we
acknowledge these study weaknesses, as the only large
prospective trial performed in the United States, the ALTS
trial is nevertheless the best available benchmark. Our
study population demographics resemble those of the
ALTS trial and our clinical follow-up also has a verifica-
tion bias derived from the same cause, leading us to accept
the ALTS trial as a good model for our practice. However,
striving for a 50% HR-HPV positive rate in ASC-US in
accord with the ALTS trial, as we have done, is not a nec-
essary part of employing HPV data to control ASC-US
rates when introducing the TIS. Maintaining HR-HPV pos-
itive rates at whatever level a given laboratory deems to be
appropriate should have equivalent utility for this pur-
pose.
Ideally any new technology would improve both the sen-
sitivity and the specificity of the Pap test. Although studies
agree that the TIS improves sensitivity, the effect on specif-
icity is far less clear. In the current environment, with dis-
cussions beginning as to whether HPV testing should
replace cytology as the preferred mode of screening [19],
it is important to remember that the primary advantage of
Pap testing lies in its superior specificity. Any substantial
increase in the ASC-US rate attributable to the TIS would
almost certainly decrease the specificity of the test, under-
mining its preferability as a screening tool. We have dem-
onstrated that the TIS does not necessarily alter the ASC-
US rate. Thus we believe it is possible to enjoy the benefits
of the TIS without deleterious effects on the specificity of
the Pap test.
Conclusion
Our results indicate that use of the TIS has had no appre-
ciable effect on the ASC-US rate in our laboratory. The per-
centage of TPPT interpreted as ASC-US was essentially the
same in cases screened by the TIS as in TPPT screened by
MS. This indicates that the use of the TIS, with its produc-
tivity benefits, appears not to be having a significant neg-
ative impact on the performance characteristics of the Pap
test. We believe that the use of the HR-HPV positivity rate
in ASC-US as a performance metric contributed to our
ability to maintain a stable ASC-US rate while using the
TIS.
List of abbreviations
ASC-US – atypical squamous cells of undetermined signif-
icance; CIN – cervical intraepithelial neoplasia; CT – cyto-
technologist; FOV – fields of view; HPV – Human
Papillomavirus; HR – high-risk; HSIL – high-grade squa-
mous intraepithelial lesion; LSIL – low-grade squamous
intraepithelial lesion; MS – manual screening; Pap test –
Papanicolaou test; SIL – squamous intraepithelial lesion;
TIS – ThinPrep® Imaging System; TPPT – ThinPrep® Papan-
icolaou test.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MT collected and compiled the study data, performed the
statistical analyses, and drafted the manuscript. DR
assisted in the design of the study and contributed to data
collection. TB assisted in the design of the study and
helped to revise the manuscript. RH supervised the study
and helped to revise the manuscript. All authors read and
approved the final manuscript.
References
1. Dawson AE: Can we change the way we screen?: the ThinPrep
Imaging System® clinical trial data and early experience.
Cancer Cytopathol 2004, 102(6):340-344.
2. Zhang FF, Banks HW, Langford SM, Davey DD: Accuracy of Thin-
Prep Imaging System in detecting low-grade squamous
intraepithelial lesions.  Arch Pathol Lab Med 2007, 131(5):773-776.
3. Biscotti CV, Dawson AE, Dziura B, Galup L, Darragh T, Rahemtulla A,
Wills-Frank L: Assisted primary screening using the auto-
mated ThinPrep Imaging System.  Am J Clin Pathol 2005,
123(2):281-287.
4. Davey E, d'Assuncao J, Irwig L, Macaskill P, Chan SF, Richards A,
Farnsworth A: Accuracy of reading liquid based cytology slides
using the ThinPrep Imager compared with conventional
cytology: prospective study.  BMJ 2007, 335(7609):31-38.
5. Chivukula M, Saad RS, Elishaev E, White S, Mauser N, Dabbs DJ:
Introduction of the Thin Prep Imaging System™ (TIS): expe-
rience in a high volume academic practice.  CytoJournal 2007,
4(1):6.
6. Dziura B, Quinn S, Richard K: Performance of an imaging system
vs. manual screening in the detection of squamous intraepi-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
CytoJournal 2008, 5:10 http://www.cytojournal.com/content/5/1/10
Page 6 of 6
(page number not for citation purposes)
thelial lesions of the uterine cervix.  Acta Cytol 2007,
50(3):309-311.
7. Lozano R: Comparison of computer-assisted and manual
screening of cervical cytology.  Gynecol Oncol 2007,
104(1):134-138.
8. Miller FS, Nagel LE, Kenny-Moynihan MB: Implementation of the
ThinPrep® Imaging System in a high-volume metropolitan
laboratory.  Diagn Cytopathol 2007, 35(4):213-217.
9. Kinney WK, Manos MM, Hurley LB, Ransley JE: Where's the high-
grade cervical neoplasia? The importance of minimally
abnormal Papanicolaou diagnoses.  Obstet Gynecol 1998,
91(6):973-976.
10. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon
D: 2006 consensus guidelines for the management of women
with abnormal cervical cancer screening tests.  Am J Obstet
Gynecol 2007, 197(4):346-355.
11. Solomon D, Schiffman M, Tarone R: Comparison of three man-
agement strategies for patients with atypical squamous cells
of undetermined significance: baseline results from a rand-
omized trial.  J Natl Cancer I 2001, 93(4):293-299.
12. Tworek JA, Jones BA, Raab S, Clary KM, Walsh MK: The value of
monitoring Human Papillomavirus DNA results for Papani-
colaou tests interpreted as atypical squamous cells of unde-
termined significance: a College of American Pathologists
Q-probes study of 68 institutions.  Arch Pathol Lab Med 2006,
131(10):1525-1532.
13. Geisinger KR, Vrbin C, Grzybicki DM, Wagner P, Garvin AJ, Raab SS:
Interobserver variability in Human Papillomavirus test
results in cervicovaginal cytologic specimens interpreted as
atypical squamous cells.  Am J Clin Pathol 2007, 128(6):1010-1014.
14. Cibas ES, Zou KH, Crum CP, Kuo F: Using the rate of positive
high-risk HPV test results for ASC-US together with the
ASC-US/SIL ratio in evaluating the performance of
cytopathologists.  Am J Clin Pathol 2008, 129(1):97-101.
15. VassarStats: [faculty.vassar.edu/lowry/VassarStats.html].  .
16. Schiffman M, Adrianza ME: ASCUS-LSIL Triage Study. Design,
methods and characteristics of trial participants.  Acta Cytol
2000, 44(5):726-742.
17. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ,
Fischer C, Lorincz A, Zahniser D: Shanxi Province Cervical Can-
cer Screening Study: a cross-sectional comparative trial of
multiple techniques to detect cervical neoplasia.  Gynecol Oncol
2001, 83(2):439-444.
18. Pan Q, Belinson JL, Li L, Pretorius RG, Qiao YL, Zhang WH, Zhang X,
Wu LY, Rong SD, Sun YT: A thin-layer, liquid-based pap test for
mass screening in an area of China with a high incidence of
cervical carcinoma. A cross-sectional, comparative study.
Acta Cytol 2003, 47(1):45-50.
19. Runowicz CD: Molecular screening for cervical cancer - time
to give up Pap tests?  NEJM 2007, 357(16):1650-1653.